These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 25216747

  • 1. c-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy.
    Hantke J, Carty L, Wagstaff LJ, Turmaine M, Wilton DK, Quintes S, Koltzenburg M, Baas F, Mirsky R, Jessen KR.
    Brain; 2014 Nov; 137(Pt 11):2922-37. PubMed ID: 25216747
    [Abstract] [Full Text] [Related]

  • 2. New evidence for secondary axonal degeneration in demyelinating neuropathies.
    Moss KR, Bopp TS, Johnson AE, Höke A.
    Neurosci Lett; 2021 Jan 23; 744():135595. PubMed ID: 33359733
    [Abstract] [Full Text] [Related]

  • 3. Nonuniform molecular features of myelinating Schwann cells in models for CMT1: distinct disease patterns are associated with NCAM and c-Jun upregulation.
    Klein D, Groh J, Wettmarshausen J, Martini R.
    Glia; 2014 May 23; 62(5):736-50. PubMed ID: 24526449
    [Abstract] [Full Text] [Related]

  • 4. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.
    Klein D, Patzkó Á, Schreiber D, van Hauwermeiren A, Baier M, Groh J, West BL, Martini R.
    Brain; 2015 Nov 23; 138(Pt 11):3193-205. PubMed ID: 26297559
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.
    Vavlitou N, Sargiannidou I, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA.
    J Neuropathol Exp Neurol; 2010 Sep 23; 69(9):945-58. PubMed ID: 20720503
    [Abstract] [Full Text] [Related]

  • 7. Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.
    Park NY, Kwak G, Doo HM, Kim HJ, Jang SY, Lee YI, Choi BO, Hong YB.
    Curr Issues Mol Biol; 2021 Nov 13; 43(3):2011-2021. PubMed ID: 34889893
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Genetic mechanisms of peripheral nerve disease.
    Stavrou M, Sargiannidou I, Christofi T, Kleopa KA.
    Neurosci Lett; 2021 Jan 18; 742():135357. PubMed ID: 33249104
    [Abstract] [Full Text] [Related]

  • 10. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.
    Kohl B, Fischer S, Groh J, Wessig C, Martini R.
    Am J Pathol; 2010 Mar 18; 176(3):1390-9. PubMed ID: 20093502
    [Abstract] [Full Text] [Related]

  • 11. Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease.
    McLean JW, Wilson JA, Tian T, Watson JA, VanHart M, Bean AJ, Scherer SS, Crossman DK, Ubogu E, Wilson SM.
    J Neurosci; 2022 Jun 22; 42(25):5085-5101. PubMed ID: 35589390
    [Abstract] [Full Text] [Related]

  • 12. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A.
    Saporta MA, Katona I, Lewis RA, Masse S, Shy ME, Li J.
    Brain; 2009 Dec 22; 132(Pt 12):3263-73. PubMed ID: 19923170
    [Abstract] [Full Text] [Related]

  • 13. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
    Lee JS, Lee JY, Song DW, Bae HS, Doo HM, Yu HS, Lee KJ, Kim HK, Hwang H, Kwak G, Kim D, Kim S, Hong YB, Lee JM, Choi BO.
    Nucleic Acids Res; 2020 Jan 10; 48(1):130-140. PubMed ID: 31713617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G, Visigalli D, Prukop T, Cervellini I, Mannino E, Venturi C, Bruzzone S, Sereda MW, Schenone A.
    Neurobiol Dis; 2016 Nov 10; 95():145-57. PubMed ID: 27431093
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy.
    Schiza N, Georgiou E, Kagiava A, Médard JJ, Richter J, Tryfonos C, Sargiannidou I, Heslegrave AJ, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Chrast R, Kleopa KA.
    Brain; 2019 May 01; 142(5):1227-1241. PubMed ID: 30907403
    [Abstract] [Full Text] [Related]

  • 18. Inherited demyelinating neuropathies with micromutations of peripheral myelin protein 22 gene.
    Taioli F, Cabrini I, Cavallaro T, Acler M, Fabrizi GM.
    Brain; 2011 Feb 01; 134(Pt 2):608-17. PubMed ID: 21252112
    [Abstract] [Full Text] [Related]

  • 19. Abnormal Schwann cell-axon interactions in CMT neuropathies. The effects of mutant Schwann cells on the axonal cytoskeleton and regeneration-associated myelination.
    Sahenk Z.
    Ann N Y Acad Sci; 1999 Sep 14; 883():415-26. PubMed ID: 10586265
    [Abstract] [Full Text] [Related]

  • 20. Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease.
    Murakami T, Sunada Y.
    Adv Exp Med Biol; 2019 Sep 14; 1190():301-321. PubMed ID: 31760652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.